Revolution Medicines receives termination notice from Genzyme (Sanofi) for collaboration deal

Revolution Medicines, Inc.

Genzyme terminated the June 2018 collaboration agreement for convenience; effective June 4, 2023.
Notice received December 6, 2022; agreement had been disclosed in prior SEC filings.
No financial impact or termination fees disclosed in the filing.
Company may lose expected future collaboration revenue from Sanofi.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Revolution Medicines, Inc. terminated Sanofi Agreement with Genzyme Corporation (effective 2023-06-04).

Action: termination
Agreement: collaboration
Counterparty: Genzyme Corporation
Effective: 2023-06-04

Exact text from the filing

On December 6, 2022, Revolution Medicines, Inc. (the “Company”) received notice of Genzyme Corporation’s decision to terminate for convenience that certain Collaborative Research, Development and Commercialization Agreement by and between the Company and Aventis, Inc., dated June 8, 2018, as assigned by Aventis, Inc. to Genzyme Corporation (as amended, the “Sanofi Agreement”).

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-300162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.